Cargando…

Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis

BACKGROUND: Autoantibodies such as anti-citrullinated protein antibodies (ACPA) are major risk factors for articular bone destruction from the earliest phases of rheumatoid arthritis (RA). The aim of the current study was to determine whether RA-associated autoantibodies also impact on systemic bone...

Descripción completa

Detalles Bibliográficos
Autores principales: Bugatti, Serena, Bogliolo, Laura, Vitolo, Barbara, Manzo, Antonio, Montecucco, Carlomaurizio, Caporali, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052789/
https://www.ncbi.nlm.nih.gov/pubmed/27716332
http://dx.doi.org/10.1186/s13075-016-1116-9
_version_ 1782458287203024896
author Bugatti, Serena
Bogliolo, Laura
Vitolo, Barbara
Manzo, Antonio
Montecucco, Carlomaurizio
Caporali, Roberto
author_facet Bugatti, Serena
Bogliolo, Laura
Vitolo, Barbara
Manzo, Antonio
Montecucco, Carlomaurizio
Caporali, Roberto
author_sort Bugatti, Serena
collection PubMed
description BACKGROUND: Autoantibodies such as anti-citrullinated protein antibodies (ACPA) are major risk factors for articular bone destruction from the earliest phases of rheumatoid arthritis (RA). The aim of the current study was to determine whether RA-associated autoantibodies also impact on systemic bone loss in patients with early disease. METHODS: Systemic bone mineral density (BMD) was measured in the lumbar spine and the hip in 155 consecutive treatment-naïve patients with early RA (median symptom duration 13 weeks). Demographic and disease-specific parameters, including clinical disease activity, ultrasonographic (US) examination of the hands and wrists, radiographic scoring of joint damage, ACPA and rheumatoid factor (RF) levels were recorded from all patients. Reduced BMD was defined as Z score ≤ -1 SD and analysed in relation to disease-related characteristics and autoantibody subgroups. RESULTS: Reduced BMD was found in 25.5 % of the patients in the spine and 19.4 % in the hip. Symptom duration, clinical and US disease activity, functional disability and radiographic damage did not significantly impact on spine and hip BMD loss in regression analyses adjusted for possible confounders (age, gender, menopausal status, current smoking, body mass index). In contrast, ACPA positivity (at any level) negatively affected the spine Z-score (adjusted OR (95 % CI) 2.76 (1.19 to 6.42)); the hip Z score was affected by high titres only (adjusted OR (95 % CI) 2.96 (1.15 to 7.66)). The association of ACPA with reduced BMD in the spine was confirmed even at low levels of RF (adjusted OR (95 % CI) 2.65 (1.01 to 7.24)), but was further increased by concomitant high RF (adjusted OR (95 % CI) 3.38 (1.11 to 10.34)). In contrast, Z scores in the hip were significantly reduced only in association with high ACPA and RF (adjusted OR (95 % CI) 4.96 (1.48 to 16.64)). CONCLUSIONS: Systemic BMD in patients with early RA is reduced in relation with ACPA positivity and high RF levels. This finding supports the notion that RA-associated autoimmunity may have a direct causative role in bone remodeling.
format Online
Article
Text
id pubmed-5052789
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50527892016-10-06 Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis Bugatti, Serena Bogliolo, Laura Vitolo, Barbara Manzo, Antonio Montecucco, Carlomaurizio Caporali, Roberto Arthritis Res Ther Research Article BACKGROUND: Autoantibodies such as anti-citrullinated protein antibodies (ACPA) are major risk factors for articular bone destruction from the earliest phases of rheumatoid arthritis (RA). The aim of the current study was to determine whether RA-associated autoantibodies also impact on systemic bone loss in patients with early disease. METHODS: Systemic bone mineral density (BMD) was measured in the lumbar spine and the hip in 155 consecutive treatment-naïve patients with early RA (median symptom duration 13 weeks). Demographic and disease-specific parameters, including clinical disease activity, ultrasonographic (US) examination of the hands and wrists, radiographic scoring of joint damage, ACPA and rheumatoid factor (RF) levels were recorded from all patients. Reduced BMD was defined as Z score ≤ -1 SD and analysed in relation to disease-related characteristics and autoantibody subgroups. RESULTS: Reduced BMD was found in 25.5 % of the patients in the spine and 19.4 % in the hip. Symptom duration, clinical and US disease activity, functional disability and radiographic damage did not significantly impact on spine and hip BMD loss in regression analyses adjusted for possible confounders (age, gender, menopausal status, current smoking, body mass index). In contrast, ACPA positivity (at any level) negatively affected the spine Z-score (adjusted OR (95 % CI) 2.76 (1.19 to 6.42)); the hip Z score was affected by high titres only (adjusted OR (95 % CI) 2.96 (1.15 to 7.66)). The association of ACPA with reduced BMD in the spine was confirmed even at low levels of RF (adjusted OR (95 % CI) 2.65 (1.01 to 7.24)), but was further increased by concomitant high RF (adjusted OR (95 % CI) 3.38 (1.11 to 10.34)). In contrast, Z scores in the hip were significantly reduced only in association with high ACPA and RF (adjusted OR (95 % CI) 4.96 (1.48 to 16.64)). CONCLUSIONS: Systemic BMD in patients with early RA is reduced in relation with ACPA positivity and high RF levels. This finding supports the notion that RA-associated autoimmunity may have a direct causative role in bone remodeling. BioMed Central 2016-10-06 2016 /pmc/articles/PMC5052789/ /pubmed/27716332 http://dx.doi.org/10.1186/s13075-016-1116-9 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Bugatti, Serena
Bogliolo, Laura
Vitolo, Barbara
Manzo, Antonio
Montecucco, Carlomaurizio
Caporali, Roberto
Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis
title Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis
title_full Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis
title_fullStr Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis
title_full_unstemmed Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis
title_short Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis
title_sort anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052789/
https://www.ncbi.nlm.nih.gov/pubmed/27716332
http://dx.doi.org/10.1186/s13075-016-1116-9
work_keys_str_mv AT bugattiserena anticitrullinatedproteinantibodiesandhighlevelsofrheumatoidfactorareassociatedwithsystemicbonelossinpatientswithearlyuntreatedrheumatoidarthritis
AT bogliololaura anticitrullinatedproteinantibodiesandhighlevelsofrheumatoidfactorareassociatedwithsystemicbonelossinpatientswithearlyuntreatedrheumatoidarthritis
AT vitolobarbara anticitrullinatedproteinantibodiesandhighlevelsofrheumatoidfactorareassociatedwithsystemicbonelossinpatientswithearlyuntreatedrheumatoidarthritis
AT manzoantonio anticitrullinatedproteinantibodiesandhighlevelsofrheumatoidfactorareassociatedwithsystemicbonelossinpatientswithearlyuntreatedrheumatoidarthritis
AT montecuccocarlomaurizio anticitrullinatedproteinantibodiesandhighlevelsofrheumatoidfactorareassociatedwithsystemicbonelossinpatientswithearlyuntreatedrheumatoidarthritis
AT caporaliroberto anticitrullinatedproteinantibodiesandhighlevelsofrheumatoidfactorareassociatedwithsystemicbonelossinpatientswithearlyuntreatedrheumatoidarthritis